Trastuzumab deruxtecan (T-DXd), a HER2-directed antibody-drug conjugate, has demonstrated promising efficacy in later-line treatment and has been approved for HER2-mutant advanced NSCLC (Goto et al., 2023; Cheng et al., 2024). Here, ERBB2 is linked to non-small cell lung carcinoma.